Skip to main content
Premium Trial:

Request an Annual Quote

CuraGen, Roche Sign Pharmacogenomics Deal

Premium

NEW HAVEN, Conn.--CuraGen said it signed a target discovery and pharmacogenomics collaboration with the Swiss life-sciences company Hoffmann-La Roche last week. Roche said it will apply CuraGen's bioinformatics and genomics expertise to the discovery of animal nutrition and human health products. The deal is designed to evaluate existing product candidates, discover new targets, and facilitate the development of drugs and diagnostic tests.

Roche will integrate data from CuraGen's SeqCalling and GeneCalling databases into it existing discovery efforts. Terms of the two-year renewable agreement were not disclosed, but Peter Fuller, CuraGen's vice-president of business development, said the successful assessment of late-stage product development candidates would increase the likelihood of CuraGen receiving near-term revenues.

Filed under

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.